

Dis Colon Rectum, Vol. 49, No. 6, June 2006,
pp. 792–809 (DOI: 10.1007/s10350-006-0536-z)

Immediately following publication of “A Consensus Document on Bowel Preparation Before Colonoscopy: Prepared by a Task Force From The American Society of Colon and Rectal Surgeons (ASCRS), The American Society for Gastrointestinal Endoscopy (ASGE), and The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES)” by Steven D. Wexner, David E. Beck, Todd H. Baron, Robert D. Fanelli, Neil Hyman, Bo Shen, and Kevin E. Wasco, the Food and Drug Administration (FDA) issued an alert regarding the use of oral sodium phosphate (OSP) products for bowel preparation. The three sponsoring societies (ASCRS, ASGE, and SAGES) wish to add the following FDA warning to the consensus document.

Ann Lowry, *Immediate Past President*, The American Society of Colon and Rectal Surgeons
Robert Hawes, *Immediate Past President*, American Society for Gastrointestinal Endoscopy
Daniel Deziel, *Immediate Past President*, Society of American Gastrointestinal and Endoscopic Surgeons

Acute phosphate nephropathy, a type of acute renal failure, is a rare, but serious event associated with the use of oral sodium phosphate (OSP) for bowel cleansing. Documented cases of acute phosphate nephropathy include 21 patients who used an OSP solution (such as Fleet Phospho-soda or Fleet ACCU-PREP) and one patient who used OSP tablets (Visicol). No cases of acute phosphate nephropathy or acute renal failure have been associated with OsmoPrep, an OSP tablet bowel preparation recently approved. Individuals at increased risk of acute phosphate nephropathy include: those of advanced age, those with kidney disease or decreased intravascular volume, and those using medicines that affect renal perfusion or function [diuretics, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and possibly nonsteroidal anti-inflammatory drugs (NSAIDs)].